The price of Erwinase Inj (L-asparaginase), used to treat patients with acute lymphoblastic leukemia (ALL), is expected to increase.

Additionally, Imfinzi, an immunotherapy drug for cancer, also succeeded in renegotiating risk-sharing agreements (RSA). Rhopressa, a treatment for open-angle glaucoma and intraocular pressure, has entered negotiations with the National Health Insurance Service (NHIS).

According to industry sources on the 16th, the NHIS posted these negotiation results and schedules.

Clinigen’s Erwinase inj was first listed in August 2019. The listing took 12 years and 5 months to be granted after the approval in South Korea. It can be covered by reimb